Developer docs
API playgroundTry for free, no card

Search company profiles

Newrotex Ltd

Full company profile

uuid00031i2

Namestring
Newrotex Ltd
Legal namestring
Newrotex Limited
Websiteurl
newrotex.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Newrotex Limited is a privately-held UK biotech company founded in 2019 and headquartered at the Wood Centre for Innovation in Oxford. The company is developing silk-based peripheral nerve repair medical devices, with its core technology platform centred on SilkAxons™ — bundles of luminal spider silk fibres harvested from Nephila spiders that act as a scaffold mimicking natural Bands of Büngner to guide axonal regeneration. SilkAxons™ is designed for use either implanted inside a harvested vein or pre-loaded into the Oxford Nerve Conduit, an off-the-shelf porous silk sheath. The 10cm implant targets large-gap peripheral nerve injuries (>5cm) where current FDA-approved devices and hollow conduits fail, and where autografts (the current standard of care) require a second surgical site, long operating times, and yield ≤50% recovery with significant complication risk.

The company holds patented silk-based technology and uses a Spidrex silk platform licensed from Oxford Biomaterials (co-founded by Founder-Director Prof Fritz Vollrath, who leads the Oxford Silk Group at the University of Oxford). Manufacturing is conducted at ISO 13485-certified facilities in Oxford. Newrotex is pre-revenue and entered first-in-human clinical trials in August 2025 at The Panama Clinic with bioaccess® as CRO partner, having secured Panama regulatory approval in July 2025 just two weeks after ethics submission. Preliminary safety data is expected Q1 2026, after which the company plans a pivotal study supporting FDA (US) and MHRA (UK) market approval filings.

The commercial model is enterprise hospital-direct sales of an off-the-shelf, room-temperature-storable medical device targeting surgeons across trauma, orthopaedics, plastic surgery, oncology, breast reconstruction, OMFS, and urology. Revenue is expected to derive from one-time device sales to hospitals and surgical centres, with future platform applications (organoids for CNS drug testing, drug/growth factor delivery, CNS/spinal cord repair) potentially monetised via licensing or co-development. Pricing is undisclosed but positioned as low-cost relative to autograft procedures. The company is grant-funded (£2.5M cumulative Innovate UK) and Knowledge-Intensive EIS eligible, with a ~10-person team led by Founder-CEO Dr Alex Woods and Chairman Chris Jones (Becton Dickinson Director).

Short descriptiontext

Newrotex Limited is a UK-based, pre-revenue biotech developing silk-based peripheral nerve repair devices — SilkAxons™ and the Oxford Nerve Conduit — for large-gap (up to 10cm) peripheral nerve injuries. The company targets hospital procurement across multiple surgical specialties and is currently in first-in-human trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersOxford, United Kingdom
HQ citystring
Oxford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peripheral nerve repair, silk biomaterials medical devices, nerve regeneration implants, biodegradable surgical conduits, regenerative medicine devices
Industry2 codes
PRIMARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAI
Neural & Spinal Cord Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Peripheral Nerve Repair Medical Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1SilkAxons™ Nerve Guide (Medical Device Sales)
TypeOne Time License
Description

Newrotex is developing silk-based nerve repair medical devices (SilkAxons™ luminal fibres and Oxford Nerve Conduit) intended for commercial sale to hospitals and surgical centres upon regulatory approval. The company is in first-in-human clinical trials with safety data expected Q1 2026, followed by market approval studies in the USA and UK. Revenue will be generated through direct device sales to healthcare institutions.

newrotex.com
2Future Platform Licensing (Silk Technology)
TypeLicensing Royalties
Description

The company notes it is developing its silk platform technology for additional applications including organoids for pharmaceutical CNS testing, drug/growth factor delivery vehicles, and central nervous system (CNS) repair. These future verticals may be monetised through licensing agreements, co-development partnerships, or direct product sales.

newrotex.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1Silk nerve conduit — off-the-shelf medical device
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Product is described as 'low-cost' and 'readily available for use in all hospitals by any surgical speciality.' No specific price points are publicly disclosed. B2B hospital procurement model implies quotation-based pricing.

newrotex.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Newrotex develops and manufactures silk-based medical devices for peripheral nerve repair. Its core products are SilkAxons® — bundles of luminal spider silk fibres harvested from Nephila spiders for implantation in a vein or hollow conduit — and the Oxford Nerve Conduit, an off-the-shelf silk-based peripheral nerve conduit pre-filled with SilkAxons® fibres. Together these provide a biodegradable, off-the-shelf scaffold for nerve re-growth that bridges gaps of up to 10cm and can be stored at room temperature.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Bridges nerve gaps up to 10cm, more than triple the reach of current FDA-approved devices
+5 more records
Product overview1 text field

Newrotex develops silk-based medical solutions for the nervous system, with two main products: SilkAxons® (luminal spider silk fibres for implantation into veins or conduits) and the Oxford Nerve Conduit (off-the-shelf silk conduit pre-filled with SilkAxons®). Both products address peripheral nerve injuries, with SilkAxons® serving as the core technology platform that can be used standalone or within the conduit system.

Product and service2 records
1SilkAxons®
CategoryPeripheral nerve repair medical device
Description

A 10cm implant made from bundles of luminal spider silk fibres harvested from Nephila spiders that can be implanted into a vein or inserted into hollow conduits to support nerve re-growth. Designed for large peripheral nerve-gap repairs (up to 10cm, more than triple the reach of current FDA-approved devices), mimics natural Bands of Büngner, and has been shown in preclinical/early clinical work to support superior axonal regeneration comparable or superior to autografts.

2Oxford Nerve Conduit
CategoryPeripheral nerve repair medical device
Description

An off-the-shelf, pre-filled silk-based peripheral nerve conduit containing SilkAxons® luminal silk fibres, negating the need to thread the implant through a vein during surgery. Features a porous tubular biocompatible sheath designed to encourage vascularisation, providing surgical ease and wide accessibility for surgeons across multiple specialties performing peripheral nerve repair.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Integra completed its acquisition of AxoGen in 2024, giving it the dominant peripheral nerve repair franchise (Avance processed nerve allograft, AcroVal, NeuraGen, NeuraWrap). Directly competes with Newrotex in large-gap PNI across trauma, plastic surgery, and OMFS.

TypeDirect peer
Description

Netherlands-based medical device company commercialising Neurolac nerve cap and Neurolac nerve conduit for peripheral nerve repair. Targets the same hollow-conduit segment of the PNI market as Newrotex's SilkAxons and Oxford Nerve Conduit.

TypeBroad incumbent
Description

Through its Synovis portfolio, Baxter markets nerve repair and reconstruction products to surgeons globally. A broader medical device incumbent with overlapping channels in trauma and reconstructive surgery.

TypeBroad incumbent
Description

Large orthopaedic and surgical device company with nerve repair and ENT/neuro surgery adjacencies. Competes for hospital budgets and OR shelf space rather than head-to-head on biomaterial nerve conduits specifically.

TypeEmerging player
Description

US developer of intraoperative nerve stimulation and identification devices used during nerve repair surgery. A complementary adjacent technology rather than a direct conduit competitor, but shares surgeon customers and OR channels.

TypeEmerging player
Description

Pittsburgh-based early-stage company developing injectable biomaterial matrices to enhance peripheral nerve regeneration. A relevant emerging peer because it directly competes in the same PNI biological scaffold space as Newrotex.

TypeRegional player
Description

UK-based medical device company accelerating NHS-focused surgical innovations, with products in adjacent surgical categories. Geographically and structurally comparable as a small UK medtech commercialising through the same hospital channels.

TypeEmerging player
Description

Australian regenerative medicine company developing nerve repair (Celgro nerve guidance) and orthobiologic products. Comparable as a small-cap, clinical-stage company commercialising a biological nerve repair technology outside the US market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Newrotex Ltd

Peripheral Nerve Repair Medical Devicesnewrotex.com

Newrotex Limited is a UK-based, pre-revenue biotech developing silk-based peripheral nerve repair devices — SilkAxons™ and the Oxford Nerve Conduit — for large-gap (up to 10cm) peripheral nerve injuries. The company targets hospital procurement across multiple surgical specialties and is currently in first-in-human trials.

What Newrotex Ltd does

Newrotex Limited is a privately-held UK biotech company founded in 2019 and headquartered at the Wood Centre for Innovation in Oxford. The company is developing silk-based peripheral nerve repair medical devices, with its core technology platform centred on SilkAxons™ — bundles of luminal spider silk fibres harvested from Nephila spiders that act as a scaffold mimicking natural Bands of Büngner to guide axonal regeneration. SilkAxons™ is designed for use either implanted inside a harvested vein or pre-loaded into the Oxford Nerve Conduit, an off-the-shelf porous silk sheath. The 10cm implant targets large-gap peripheral nerve injuries (>5cm) where current FDA-approved devices and hollow conduits fail, and where autografts (the current standard of care) require a second surgical site, long operating times, and yield ≤50% recovery with significant complication risk.

The company holds patented silk-based technology and uses a Spidrex silk platform licensed from Oxford Biomaterials (co-founded by Founder-Director Prof Fritz Vollrath, who leads the Oxford Silk Group at the University of Oxford). Manufacturing is conducted at ISO 13485-certified facilities in Oxford. Newrotex is pre-revenue and entered first-in-human clinical trials in August 2025 at The Panama Clinic with bioaccess® as CRO partner, having secured Panama regulatory approval in July 2025 just two weeks after ethics submission. Preliminary safety data is expected Q1 2026, after which the company plans a pivotal study supporting FDA (US) and MHRA (UK) market approval filings.

The commercial model is enterprise hospital-direct sales of an off-the-shelf, room-temperature-storable medical device targeting surgeons across trauma, orthopaedics, plastic surgery, oncology, breast reconstruction, OMFS, and urology. Revenue is expected to derive from one-time device sales to hospitals and surgical centres, with future platform applications (organoids for CNS drug testing, drug/growth factor delivery, CNS/spinal cord repair) potentially monetised via licensing or co-development. Pricing is undisclosed but positioned as low-cost relative to autograft procedures. The company is grant-funded (£2.5M cumulative Innovate UK) and Knowledge-Intensive EIS eligible, with a ~10-person team led by Founder-CEO Dr Alex Woods and Chairman Chris Jones (Becton Dickinson Director).

Newrotex Ltd firmographics

Firmographics
Name
Newrotex Ltd
Legal name
Newrotex Limited
Website
https://newrotex.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Newrotex Limited is a UK-based, pre-revenue biotech developing silk-based peripheral nerve repair devices — SilkAxons™ and the Oxford Nerve Conduit — for large-gap (up to 10cm) peripheral nerve injuries. The company targets hospital procurement across multiple surgical specialties and is currently in first-in-human trials.
Ownership category
akta.pro rank

Newrotex Ltd industry classification

Industry
Product category
Peripheral Nerve Repair Medical Devices
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAI
Neural & Spinal Cord Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Peripheral nerve repair
  • Silk biomaterials medical devices
  • Nerve regeneration implants
  • Biodegradable surgical conduits
  • Regenerative medicine devices

Where Newrotex Ltd is headquartered

Location

Headquarters

HQ city
Oxford
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Newrotex Ltd business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. SilkAxons™ Nerve Guide (Medical Device Sales): Newrotex is developing silk-based nerve repair medical devices (SilkAxons™ luminal fibres and Oxford Nerve Conduit) intended for commercial sale to hospitals and surgical centres upon regulatory approval. The company is in first-in-human clinical trials with safety data expected Q1 2026, followed by market approval studies in the USA and UK. Revenue will be generated through direct device sales to healthcare institutions.
  2. Future Platform Licensing (Silk Technology): The company notes it is developing its silk platform technology for additional applications including organoids for pharmaceutical CNS testing, drug/growth factor delivery vehicles, and central nervous system (CNS) repair. These future verticals may be monetised through licensing agreements, co-development partnerships, or direct product sales.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractSilk nerve conduit — off-the-shelf medical device

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Newrotex Ltd product offering

Product offering

Core offering

Newrotex develops and manufactures silk-based medical devices for peripheral nerve repair. Its core products are SilkAxons® — bundles of luminal spider silk fibres harvested from Nephila spiders for implantation in a vein or hollow conduit — and the Oxford Nerve Conduit, an off-the-shelf silk-based peripheral nerve conduit pre-filled with SilkAxons® fibres. Together these provide a biodegradable, off-the-shelf scaffold for nerve re-growth that bridges gaps of up to 10cm and can be stored at room temperature.

Product overview

Newrotex develops silk-based medical solutions for the nervous system, with two main products: SilkAxons® (luminal spider silk fibres for implantation into veins or conduits) and the Oxford Nerve Conduit (off-the-shelf silk conduit pre-filled with SilkAxons®). Both products address peripheral nerve injuries, with SilkAxons® serving as the core technology platform that can be used standalone or within the conduit system.

Differentiator

Problem solved

Functional benefit

Products and services

  • SilkAxons® A 10cm implant made from bundles of luminal spider silk fibres harvested from Nephila spiders that can be implanted into a vein or inserted into hollow conduits to support nerve re-growth. Designed for large peripheral nerve-gap repairs (up to 10cm, more than triple the reach of current FDA-approved devices), mimics natural Bands of Büngner, and has been shown in preclinical/early clinical work to support superior axonal regeneration comparable or superior to autografts.
  • Oxford Nerve Conduit An off-the-shelf, pre-filled silk-based peripheral nerve conduit containing SilkAxons® luminal silk fibres, negating the need to thread the implant through a vein during surgery. Features a porous tubular biocompatible sheath designed to encourage vascularisation, providing surgical ease and wide accessibility for surgeons across multiple specialties performing peripheral nerve repair.

Quantifiable outcome

  • Bridges nerve gaps up to 10cm, more than triple the reach of current FDA-approved devices
  • +5 more outcomes

Companies that use Newrotex Ltd

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Newrotex Ltd technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Newrotex Ltd partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Newrotex Ltd competitors and assessment

Company assessment

Direct peers

  • Integra LifeSciences (AxoGen): Integra completed its acquisition of AxoGen in 2024, giving it the dominant peripheral nerve repair franchise (Avance processed nerve allograft, AcroVal, NeuraGen, NeuraWrap). Directly competes with Newrotex in large-gap PNI across trauma, plastic surgery, and OMFS.
  • Polyganics: Netherlands-based medical device company commercialising Neurolac nerve cap and Neurolac nerve conduit for peripheral nerve repair. Targets the same hollow-conduit segment of the PNI market as Newrotex's SilkAxons and Oxford Nerve Conduit.

Broad incumbents

  • Baxter International (Synovis): Through its Synovis portfolio, Baxter markets nerve repair and reconstruction products to surgeons globally. A broader medical device incumbent with overlapping channels in trauma and reconstructive surgery.
  • Stryker: Large orthopaedic and surgical device company with nerve repair and ENT/neuro surgery adjacencies. Competes for hospital budgets and OR shelf space rather than head-to-head on biomaterial nerve conduits specifically.

Emerging players

  • Checkpoint Surgical: US developer of intraoperative nerve stimulation and identification devices used during nerve repair surgery. A complementary adjacent technology rather than a direct conduit competitor, but shares surgeon customers and OR channels.
  • Renerva: Pittsburgh-based early-stage company developing injectable biomaterial matrices to enhance peripheral nerve regeneration. A relevant emerging peer because it directly competes in the same PNI biological scaffold space as Newrotex.
  • Orthocell: Australian regenerative medicine company developing nerve repair (Celgro nerve guidance) and orthobiologic products. Comparable as a small-cap, clinical-stage company commercialising a biological nerve repair technology outside the US market.

Regional players

  • Medovate: UK-based medical device company accelerating NHS-focused surgical innovations, with products in adjacent surgical categories. Geographically and structurally comparable as a small UK medtech commercialising through the same hospital channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Newrotex Ltd social profiles

Digital presence

Newrotex Ltd compliance and trust

Trust signal

Compliance1 record

Newrotex Ltd financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Newrotex Ltd leadership team

Management profile

Number of profiles

Profiles13 records

Newrotex Ltd funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Newrotex Ltd M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Newrotex Ltd

What does Newrotex Ltd do?

Newrotex develops and manufactures silk-based medical devices for peripheral nerve repair. Its core products are SilkAxons® — bundles of luminal spider silk fibres harvested from Nephila spiders for implantation in a vein or hollow conduit — and the Oxford Nerve Conduit, an off-the-shelf silk-based peripheral nerve conduit pre-filled with SilkAxons® fibres. Together these provide a biodegradable, off-the-shelf scaffold for nerve re-growth that bridges gaps of up to 10cm and can be stored at room temperature.

Is Newrotex Ltd a public or private company?

Newrotex Ltd is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Newrotex Ltd founded?

Newrotex Ltd was founded in 2019. It employs 1 to 10 people.

Where is Newrotex Ltd based?

Newrotex Ltd is headquartered in Oxford, United Kingdom, in the Europe region.

How does Newrotex Ltd make money?

Two revenue lines are on record. SilkAxons™ Nerve Guide (Medical Device Sales) is the primary driver. The others are future Platform Licensing (Silk Technology).

Who are Newrotex Ltd's main competitors?

Direct peers on record are Integra LifeSciences (AxoGen) and Polyganics. Broad incumbents are Baxter International (Synovis) and Stryker. Emerging players are Checkpoint Surgical, Renerva and Orthocell. Medovate is listed as a regional player.

Does Newrotex Ltd have an API?

No public API is recorded for Newrotex Ltd.

What industry is Newrotex Ltd in?

Newrotex Ltd's product category is Peripheral Nerve Repair Medical Devices. Its primary akta.pro industry code is HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials), with a secondary code of HLAAAGAI, Neural & Spinal Cord Regeneration. Its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales